What ARK does
ARK develops WISKY, an AI screening platform that analyzes retinal images to detect risk of three leading blindness-causing conditions (glaucoma, diabetic retinopathy, macular degeneration) as well as cardiovascular and chronic kidney disease, plus OREUM, a chronic-disease management platform, and its own automated fundus cameras. The company says it secured orders or reservations from about 1,000 Korean clinics within its first year and delivered to more than 700 of them, with distribution expanded through a partnership with Daewoong Pharmaceutical. ARK was founded in Busan in 2018, as a Busan National University technology-holding spin-off, and also has offices in Seoul and Incheon.
ARK is a healthcare tool on Falcoscan. AI retinal screening platform catching heart and kidney disease early. Falcoscan rates ARK with an Opportunity score of 84/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. ARK is founded in 2018, currently at Series_a stage. Pricing: Paid.